Determination of the median effective dose (ED₅₀) of oliceridine combined with propofol for inhibiting gastroscope insertion responses in adult patients undergoing painless gastroscopy
Frontiers in Medicine · 05.08.2026 · 13
DOI: 10.3389/fmed.2026.1877936 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Medicine, online erschienen am 05.08.2026. Verfasst von Xiaojing Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, China. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Propofol is the most frequently administered intravenous anesthetic in painless gastroscopy. Oliceridine, a novel μ -opioid receptor agonist, exhibits analgesic effects while reducing adverse reactions. The combination of propofol and oliceridine has shown promising efficacy in clinical practice. However, the exploration of the specific effective dosage of oliceridine in painless gastroscopy is still in its early stages. This study aimed to determine the median effective dose (ED₅₀) of oliceridine when combined with propofol during painless gastroscopy.
Methods
Patients aged 18–85 years with American Society of Anesthesiologists (ASA) physical status I to III undergoing painless gastroscopy were enrolled. They received an intravenous injection of oliceridine, followed by propofol at a dose of 1.5 mg/kg. The initial dose of oliceridine for the first patient was 20 μg/kg, and subsequent doses were adjusted using Dixon’s up-and-down method based on the previous patient’s response to gastroscope insertion—with a 1 μg/kg increase or decrease depending on the observed response. Data collection continued until 7 crossover points were obtained. Probit regression and bootstrapping methods were used to calculate the ED₅₀ and its 95% confidence intervals (CI). Hemodynamic parameters and perioperative adverse events were recorded.
Results
A total of 24 patients were included in the study. The ED₅₀ of oliceridine combined with propofol (1.5 mg/kg) for inhibiting the response to gastroscope insertion in patients undergoing painless gastroscopy was 19.33 μg/kg (95% CI, 17.41 ~ 21.98 μg/kg). The vital signs of all patients remained within the predefined acceptable limits, and no serious adverse events occurred.
Conclusion
The ED₅₀ of oliceridine combined with propofol (1.5 mg/kg) for inhibiting gastroscope insertion responses in adult patients undergoing painless gastroscopy is 19.33 μg/kg. Clinical trials registration ChiCTR2500105523.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anesthesiology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
- Department of Anesthesiology, The People's Hospital of Rugao, Rugao Hospital Affiliated to Nantong University, Rugao, Jiangsu, China.
- Department of Anesthesiology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Zitieren
APA
Zhang, X., Qin, W., Zhang, X., Liang, W., Ren, Z., Ma, Q., Zhou, L., & Zheng, L. (2026). Determination of the median effective dose (ED₅₀) of oliceridine combined with propofol for inhibiting gastroscope insertion responses in adult patients undergoing painless gastroscopy. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1877936
Vancouver
Zhang X, Qin W, Zhang X, Liang W, Ren Z, Ma Q, et al. Determination of the median effective dose (ED₅₀) of oliceridine combined with propofol for inhibiting gastroscope insertion responses in adult patients undergoing painless gastroscopy. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1877936
BibTeX
@article{Zhang2026,
author = {Zhang, Xiaojing and Qin, Weimin and Zhang, Xinying and Liang, Wenbo and Ren, Zhiqiang and Ma, Qing and Zhou, Li and Zheng, Longbin},
title = {Determination of the median effective dose (ED₅₀) of oliceridine combined with propofol for inhibiting gastroscope insertion responses in adult patients undergoing painless gastroscopy},
journal = {Frontiers in Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fmed.2026.1877936}
}
EUVIMED